Tau-targeting active immunotherapy slows progression and reduces pathology in mouse models of tauopathy.

As illustrated in Figure 4A , the onset of ataxia symptoms appears delayed in immunized transgenic mice; this delay in onset, however, did not reach statistical significance (p5555kb 35% vs. vehicle 20%, p = 0.0527, Figure 4A ).

also in 111,027 other papers